145 related articles for article (PubMed ID: 24587255)
1. A compensatory role of NF-κB to p53 in response to 5-FU-based chemotherapy for gastric cancer cell lines.
Endo F; Nishizuka SS; Kume K; Ishida K; Katagiri H; Ishida K; Sato K; Iwaya T; Koeda K; Wakabayashi G
PLoS One; 2014; 9(2):e90155. PubMed ID: 24587255
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia-inducible factor 1alpha determines gastric cancer chemosensitivity via modulation of p53 and NF-kappaB.
Rohwer N; Dame C; Haugstetter A; Wiedenmann B; Detjen K; Schmitt CA; Cramer T
PLoS One; 2010 Aug; 5(8):e12038. PubMed ID: 20706634
[TBL] [Abstract][Full Text] [Related]
3. Molecular marker identification for relapse prediction in 5-FU-based adjuvant chemotherapy in gastric and colorectal cancers.
Ishida K; Nishizuka SS; Chiba T; Ikeda M; Kume K; Endo F; Katagiri H; Matsuo T; Noda H; Iwaya T; Yamada N; Fujiwara H; Takahashi M; Itabashi T; Uesugi N; Maesawa C; Tamura G; Sugai T; Otsuka K; Koeda K; Wakabayashi G
PLoS One; 2012; 7(8):e43236. PubMed ID: 22905237
[TBL] [Abstract][Full Text] [Related]
4. Troxerutin (TXN) potentiated 5-Fluorouracil (5-Fu) treatment of human gastric cancer through suppressing STAT3/NF-κB and Bcl-2 signaling pathways.
Xu GY; Tang XJ
Biomed Pharmacother; 2017 Aug; 92():95-107. PubMed ID: 28531805
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of inducible NF-kappaB activity reduces chemoresistance to 5-fluorouracil in human stomach cancer cell line.
Uetsuka H; Haisa M; Kimura M; Gunduz M; Kaneda Y; Ohkawa T; Takaoka M; Murata T; Nobuhisa T; Yamatsuji T; Matsuoka J; Tanaka N; Naomoto Y
Exp Cell Res; 2003 Sep; 289(1):27-35. PubMed ID: 12941601
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex: thymidylate synthase dependent and independent networks.
Wang W; McLeod HL; Cassidy J; Collie-Duguid ES
Cancer Chemother Pharmacol; 2007 May; 59(6):839-45. PubMed ID: 17119966
[TBL] [Abstract][Full Text] [Related]
7. Inducible nuclear factor-kappaB activation contributes to chemotherapy resistance in gastric cancer.
Camp ER; Li J; Minnich DJ; Brank A; Moldawer LL; MacKay SL; Hochwald SN
J Am Coll Surg; 2004 Aug; 199(2):249-58. PubMed ID: 15275881
[TBL] [Abstract][Full Text] [Related]
8. HOXA13 contributes to gastric carcinogenesis through DHRS2 interacting with MDM2 and confers 5-FU resistance by a p53-dependent pathway.
Han Y; Song C; Wang J; Tang H; Peng Z; Lu S
Mol Carcinog; 2018 Jun; 57(6):722-734. PubMed ID: 29436749
[TBL] [Abstract][Full Text] [Related]
9. TWEAK/Fn14 signaling mediates gastric cancer cell resistance to 5-fluorouracil via NF-κB activation.
Kwon OH; Kim JH; Kim SY; Kim YS
Int J Oncol; 2014 Feb; 44(2):583-90. PubMed ID: 24337061
[TBL] [Abstract][Full Text] [Related]
10. LY294002 may overcome 5-FU resistance via down-regulation of activated p-AKT in Epstein-Barr virus-positive gastric cancer cells.
Shin JY; Kim JO; Lee SK; Chae HS; Kang JH
BMC Cancer; 2010 Aug; 10():425. PubMed ID: 20704765
[TBL] [Abstract][Full Text] [Related]
11. Lentivirus-mediated shRNA targeting of cyclin D1 enhances the chemosensitivity of human gastric cancer to 5-fluorouracil.
Seo JH; Jeong ES; Lee KS; Heo SH; Jeong DG; Choi YK
Int J Oncol; 2013 Dec; 43(6):2007-14. PubMed ID: 24100731
[TBL] [Abstract][Full Text] [Related]
12. Survivin up-regulates the expression of breast cancer resistance protein (BCRP) through attenuating the suppression of p53 on NF-κB expression in MCF-7/5-FU cells.
Wang QP; Wang Y; Wang XD; Mo XM; Gu J; Lu ZY; Pan ZL; Zhu YX
Int J Biochem Cell Biol; 2013 Sep; 45(9):2036-44. PubMed ID: 23838170
[TBL] [Abstract][Full Text] [Related]
13. Chitosan-Gelatin-EGCG Nanoparticle-Meditated LncRNA TMEM44-AS1 Silencing to Activate the P53 Signaling Pathway for the Synergistic Reversal of 5-FU Resistance in Gastric Cancer.
Zhou M; Dong J; Huang J; Ye W; Zheng Z; Huang K; Pan Y; Cen J; Liang Y; Shu G; Ye S; Lu X; Zhang J
Adv Sci (Weinh); 2022 Aug; 9(22):e2105077. PubMed ID: 35717675
[TBL] [Abstract][Full Text] [Related]
14. The role of SIRT5 and p53 proteins in the sensitivity of colon cancer cells to chemotherapeutic agent 5-Fluorouracil.
Ekremoglu O; Koc A
Mol Biol Rep; 2021 Jul; 48(7):5485-5495. PubMed ID: 34279763
[TBL] [Abstract][Full Text] [Related]
15. Aspirin suppresses chemoresistance and enhances antitumor activity of 5-Fu in 5-Fu-resistant colorectal cancer by abolishing 5-Fu-induced NF-κB activation.
Fu J; Xu Y; Yang Y; Liu Y; Ma L; Zhang Y
Sci Rep; 2019 Nov; 9(1):16937. PubMed ID: 31729451
[TBL] [Abstract][Full Text] [Related]
16. rpL3 promotes the apoptosis of p53 mutated lung cancer cells by down-regulating CBS and NFκB upon 5-FU treatment.
Russo A; Saide A; Cagliani R; Cantile M; Botti G; Russo G
Sci Rep; 2016 Dec; 6():38369. PubMed ID: 27924828
[TBL] [Abstract][Full Text] [Related]
17. The effect of adenovirus expressing wild-type p53 on 5-fluorouracil chemosensitivity is related to p53 status in pancreatic cancer cell lines.
Eisold S; Linnebacher M; Ryschich E; Antolovic D; Hinz U; Klar E; Schmidt J
World J Gastroenterol; 2004 Dec; 10(24):3583-9. PubMed ID: 15534911
[TBL] [Abstract][Full Text] [Related]
18. New uracil analog U-332 is an inhibitor of NF-κB in 5-fluorouracil-resistant human leukemia HL-60 cell line.
Długosz-Pokorska A; Pięta M; Kędzia J; Janecki T; Janecka A
BMC Pharmacol Toxicol; 2020 Mar; 21(1):18. PubMed ID: 32122395
[TBL] [Abstract][Full Text] [Related]
19. MEL-pep, an analog of melittin, disrupts cell membranes and reverses 5-fluorouracil resistance in human hepatocellular carcinoma cells.
Ke M; Dong J; Wang Y; Zhang J; Zhang M; Wu Z; Lv Y; Wu R
Int J Biochem Cell Biol; 2018 Aug; 101():39-48. PubMed ID: 29800725
[TBL] [Abstract][Full Text] [Related]
20. Prognostic role of p53 codon 72 polymorphism in gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy.
Huang ZH; Hua D; Li LH; Zhu JD
J Cancer Res Clin Oncol; 2008 Oct; 134(10):1129-34. PubMed ID: 18357466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
